Deuruxolitinib
Appearance
![]() | |
Clinical data | |
---|---|
Trade names | Leqselvi |
Other names | CTP-543 |
License data | |
Routes of administration | By mouth |
Drug class | Janus kinase inhibitor |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII |
|
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C17H18N6 |
Molar mass | 306.373 g·mol−1 |
3D model (JSmol) | |
| |
|
Deuruxolitinib, sold under the brand name Leqselvi, is a medication used for the treatment of alopecia areata.[1] It is a Janus kinase inhibitor selective for JAK1 and JAK2.[2]
Deuruxolitinib was approved for medical use in the United States in July 2024.[1][3]
Medical uses
[edit]Deuruxolitinib is indicated for the treatment of adults with severe alopecia areata.[1]
Side effects
[edit]The FDA prescribing label for deuruxolitinib contains a boxed warning for serious infections; malignancies; cardiovascular death, myocardial infarction, and stroke; and thrombosis.[4]
Society and culture
[edit]Names
[edit]Deuruxolitinib is the international nonproprietary name[5] and the United States Adopted Name.[6]
References
[edit]- ^ a b c d https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217900Orig1s000ltr.pdf
- ^ King, Brett; Mesinkovska, Natasha; Mirmirani, Paradi; Bruce, Suzanne; Kempers, Steve; Guttman-Yassky, Emma; et al. (August 2022). "Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata". Journal of the American Academy of Dermatology. 87 (2): 306–313. doi:10.1016/j.jaad.2022.03.045. ISSN 1097-6787. PMID 35364216. S2CID 247866262.
- ^ "U.S. FDA Approves Leqselvi (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata" (Press release). Sun Pharmaceutical. 25 July 2024. Retrieved 26 July 2024 – via PR Newswire.
- ^ http://www.leqselvi.com/&a=Prescribing Information
- ^ World Health Organization (2021). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 86". WHO Drug Information. 35 (3). hdl:10665/346562.
- ^ "Deuruxolitinib". American Medical Association. Retrieved 27 July 2024.
Further reading
[edit]- Passeron T, King B, Seneschal J, Steinhoff M, Jabbari A, Ohyama M, et al. (2023). "Inhibition of T-cell activity in alopecia areata: recent developments and new directions". Frontiers in Immunology. 14: 1243556. doi:10.3389/fimmu.2023.1243556. PMC 10657858. PMID 38022501.
External links
[edit]- "Deuruxolitinib (Code C175770)". NCI Thesaurus.
- "Deuruxolitinib Phosphate (Code C175771)". NCI Thesaurus.
- Clinical trial number NCT04518995 for "Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1) (THRIVE-AA1)" at ClinicalTrials.gov
- Clinical trial number NCT04797650 for "Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) (THRIVE-AA2)" at ClinicalTrials.gov